European Association of Euro-Pharmaceutical Companies

The British, German, Dutch, Danish, Swedish and Norwegian healthcare systems make direct savings of hundreds of million of Euros every year thanks to parallel-traded medicines.


To these direct savings must be added a much higher amount of indirect savings as a result of parallel trade being the only form of price competition to monopolistic patent-protected brands.

Without parallel trade, healthcare contributions by the tax-payer would be higher and many patients would face paying more at a time of growing need for prescribed medicines.

With newer and improved medicines increasingly expensive, and with the range of parallel-traded products expanding with more countries involved as parallel trade destinations, there is a huge potential for savings to increase - as long as supplies are not jeopardised by artificial barriers - such as quota systems or dual pricing by manufacturers - to free movement within the EU.